Clinical trial registry record

A Dose Escalation Study of IBI333 in Subjects With Neovascular Age-related Macular Degeneration

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 1 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated September 4, 2024.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT05639530
Last registry update
September 4, 2024
Status
Completed
Phase
Phase 1
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Enrollment
17
Countries
China
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1
Study design
NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
17
Population
ALL · 50 Years
Duration
2023-02-27 to 2024-04-23
Intervention
IBI333
Comparator
Not reported
Outcomes measured
Safety and tolerance indicators — Through study completion, a maximum of 24 weeks; The area under the curve (AUC) of serum concentration of the drug after the administration. — Through study completion,…; Maximum concentration (Cmax) of the drug after the administration. — Through study completion, a maximum of 24 weeks; Time at which maximum concentration (Tmax) occurs for the drug after the administration. — Through study completion, a…; The half-life (t1/2) of drug after the administration . — Through study completion, a maximum of 24 weeks; Number of participants with anti-drug antibodies or neutralizing antibodies . — Through study completion, a maximum of…; Changes of BCVA measured by ETDRS chart from baseline. — Through study completion, a maximum of 24 weeks; Changes of CST measured by spectral domain optical coherence tomography (SD-OCT) from baseline. — Through study complet…; Proportion of subjects without intraretinal or subretinal fluid on SD-OCT. — Through study completion, a maximum of 24…; Change of height of pigment epithelial detachment from baseline on SD-OCT. — Through study completion, a maximum of 24…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON